Zalifrelimab
- Generic Name
- Zalifrelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2148321-69-9
- Unique Ingredient Identifier
- FE7L22H028
- Background
Zalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
- Conditions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Agenus Inc.
- Registration Number
- NCT05572970
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
- Conditions
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-08-21
- Target Recruit Count
- 36
- Registration Number
- NCT04943848
- Locations
- 🇺🇸
Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
🇺🇸Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Children's Health Orange County (CHOC), Orange, California, United States
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Nelum Corp
- Target Recruit Count
- 28
- Registration Number
- NCT04827953
- Locations
- 🇪🇸
Hospital Universitario Virgen De La Victoria, Málaga, AndalucÃa, Spain
🇪🇸Hospital Universitario Miguel Servet, Zaragoza, Aragón, Spain
🇪🇸Hospital ClÃnico Universitario de Santiago, Santiago De Compostela, A Coruña, Spain
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 28
- Registration Number
- NCT04028063
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.